Medifast Non-GAAP EPS of -$0.19 beats by $0.16, revenue of $72.05M beats by $0.75M (MED:NYSE)
Medifast reported Q3 Non-GAAP EPS of -$0.19, beating estimates by $0.16. Revenue was $72.05M, down 19.4% Y/Y but exceeding expectations by $0.75M. The company had 10,200 independent active earning coaches. According to the company, revenue decreased from $89.4M in the prior year period.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, though the revenue beat offers a modest positive note.
Market read
First‑time earnings disclosure for the quarter; provides fresh data for traders.
What to watch
Management may be pursuing new product lines or pricing strategies not reflected in the current quarter.
Background
Medifast released its Q3 2026 earnings, showing a loss per share but a slight revenue beat.
Ticker impact
Q3 2026 Non-GAAP EPS of -$0.19 beats expectations by $0.16 and revenue of $72.05M beats by $0.75M.
likely pressure as the market prices in the loss despite the revenue beat
Negative EPS signals weaker profitability; investors may sell on the surprise loss.
Market effects
Weight loss and nutrition segment may see modest impact as Medifast's results reflect broader consumer discretionary trends.
U.S. small‑cap health‑and‑wellness stocks could see slight downside pressure.
Limited; primarily affects U.S. investors focused on niche health‑food companies.
Counterpoint
The revenue beat could signal a turnaround if cost controls improve, offering a buying opportunity.
Key entities
- CompanyMedifast
U.S. health‑and‑wellness company (ticker MED).
